Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies.
Kastritis E, Theodorakakou F, Ntanasis-Stathopoulos I, Spiliopoulou V, Solia E, Malandrakis P, Syrigou R, Kokkali N, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Roussou M, Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: kanellias n. Hemasphere. 2023 Nov 3;7(11):e975. doi: 10.1097/HS9.0000000000000975. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37936678 Free PMC article. No abstract available.
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.
Ziogas DC, Terpos E, Gavriatopoulou M, Migkou M, Fotiou D, Roussou M, Kanellias N, Tatouli I, Eleutherakis-Papaiakovou E, Panagiotidis I, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA. Ziogas DC, et al. Among authors: kanellias n. Leuk Lymphoma. 2018 Apr;59(4):983-987. doi: 10.1080/10428194.2017.1361031. Epub 2017 Aug 7. Leuk Lymphoma. 2018. PMID: 28782413 No abstract available.
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M, Ziogas DC, Kanellias N, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: kanellias n. Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22. Blood. 2018. PMID: 29167176 Free article. No abstract available.
Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy.
Terpos E, Kostopoulos IV, Kastritis E, Ntanasis-Stathopoulos I, Migkou M, Rousakis P, Argyriou AT, Kanellias N, Fotiou D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ziogas DC, Papanota AM, Spyropoulou-Vlachou M, Trougakos IP, Tsitsilonis OE, Paiva B, Dimopoulos MA. Terpos E, et al. Among authors: kanellias n. Hemasphere. 2019 Oct 1;3(6):e300. doi: 10.1097/HS9.0000000000000300. eCollection 2019 Dec. Hemasphere. 2019. PMID: 31976475 Free PMC article.
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period.
Terpos E, Ntanasis-Stathopoulos I, Roussou M, Kanellias N, Fotiou D, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: kanellias n. Ann Hematol. 2020 Jun;99(6):1257-1264. doi: 10.1007/s00277-020-04060-z. Epub 2020 May 7. Ann Hematol. 2020. PMID: 32382768
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, Dialoupi I, Malandrakis P, Theodorakakou F, Kastritis E, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: kanellias n. Hemasphere. 2020 May 21;4(3):e381. doi: 10.1097/HS9.0000000000000381. eCollection 2020 Jun. Hemasphere. 2020. PMID: 32647800 Free PMC article. No abstract available.
Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis.
Kastritis E, Terpos E, Sklirou A, Theodorakakou F, Fotiou D, Papanagnou ED, Bagratuni T, Kanellias N, Gavriatopoulou M, Trougakos IP, Dimopoulos MA. Kastritis E, et al. Among authors: kanellias n. Hemasphere. 2021 Jul 15;5(8):e614. doi: 10.1097/HS9.0000000000000614. eCollection 2021 Aug. Hemasphere. 2021. PMID: 34278231 Free PMC article. No abstract available.
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, Fotiou D, Papanagnou ED, Migkou M, Theodorakakou F, Roussou M, Eleutherakis-Papaiakovou E, Kanellias N, Trougakos IP, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: kanellias n. Blood Cancer J. 2021 Aug 2;11(8):138. doi: 10.1038/s41408-021-00530-3. Blood Cancer J. 2021. PMID: 34341335 Free PMC article.
86 results